指南与共识头颈与中枢神经肿瘤

弥漫性胶质瘤切除程度分类的循证推荐

Evidence-based recommendations on categories for extent of resection in diffuse glioma.
指南 / 共识 · Eur J Cancer · 2021-04-02

该循证推荐基于全面文献综述制定,针对弥漫性胶质瘤提出「活检、部分切除、次全切除、近全切除、完全切除、超全切除」六类切除程度定义。定义依据胶质母细胞瘤对比增强与非增强肿瘤的缩减,以及WHO 2或3级胶质瘤T2/FLAIR高信号肿瘤的缩减,并纳入相对体积缩减百分比与绝对残留体积(cm³)。证据级别为IIB至IV级,旨在标准化命名并作为未来临床试验分层因素。

要点

  • 提出六类切除程度标准化命名框架,涵盖活检至超全切除。
  • 胶质母细胞瘤依据对比增强与非增强肿瘤缩减定义切除程度。
  • WHO 2或3级胶质瘤依据T2/FLAIR高信号肿瘤缩减定义切除程度。

核心结论

  • 所提出的切除程度分类为基于既往研究标准化命名提供了框架。
  • 该分类最终可能作为未来临床试验的分层因素。

研究设计与样本

  • 基于全面文献综述制定循证专家推荐。
  • 推荐针对活检、部分切除、次全切除、近全切除、完全切除和超全切除六类切除程度。

主要发现

  • 胶质母细胞瘤的切除程度定义基于对比增强与非增强肿瘤的缩减。
  • WHO 2或3级胶质瘤的切除程度定义基于T2/FLAIR高信号肿瘤的缩减。
  • 分类同时纳入相对肿瘤体积缩减百分比与绝对残留肿瘤体积(cm³)。
  • 所提分类的证据级别范围为IIB至IV级。

关键数值与推荐

  • 活检、部分切除、次全切除、近全切除、完全切除、超全切除六类定义。
  • 胶质母细胞瘤以对比增强与非增强肿瘤缩减为定义依据。
  • WHO 2或3级胶质瘤以T2/FLAIR高信号肿瘤缩减为定义依据。
  • 测量纳入相对体积缩减百分比与绝对残留体积(cm³)。
  • 证据级别为IIB至IV级。

临床怎么用

  • 临床可采用该六类命名框架标准化切除程度的描述与记录。
  • 评估切除程度时应同时报告相对体积缩减百分比与绝对残留体积。
  • 胶质母细胞瘤与WHO 2或3级胶质瘤应采用各自的影像学定义依据。

局限性

  • 所提分类的局限性在文中已讨论。
  • 分类需在前瞻性、分子定义明确的队列中评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Surgical resection represents the standard of care in diffuse glioma, and more extensive tumour resection appears to be associated with favourable outcome. Up to now, terminology to describe extent of resection has been inconsistently applied across clinical trials which hampers comparative analysis of cohorts between different studies. Based on a comprehensive literature review, we developed evidence-based expert recommendations on categories for extent of resection. Recommendations are formulated for the categories 'biopsy', 'partial resection', 'subtotal resection', 'near total resection', 'complete resection' and 'supramaximal resection'. Definitions rest on reduction of contrast- and non-contrast-enhancing tumour in glioblastoma, and on reduction of T2/FLAIR-hyperintense tumour in gliomas WHO grade 2 or 3. Both relative reduction of tumour volume (in percentage) as a measurement of surgical efficacy and absolute residual tumour volume (in cm3) as a measurement of remaining tumour burden are incorporated into the categories for extent of resection. Class of evidence for the proposed categories ranges from class IIB to IV. Limitations of the suggested categories are discussed. The proposed categories on extent of resection offer a framework to standardize nomenclature based on previous studies, and will need to be evaluated in prospective, molecularly well-defined cohorts. Our categories may eventually help as a stratification factor for future clinical trials.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Karschnia P, Vogelbaum MA, van den Bent M, et al. Evidence-based recommendations on categories for extent of resection in diffuse glioma. Eur J Cancer. 2021. PMID: 33819718. doi:10.1016/j.ejca.2021.03.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。